ArticleClinical cancer research : an official journal of the American Association for Cancer Research2020
PARP Inhibition Enhances Radiotherapy of SMAD4-Deficient Human Head and Neck Squamous Cell Carcinomas in Experimental Models.
Open access · greenAbstract read
In one paragraph
Article in Clinical cancer research : an official journal of the American Association for Cancer Research, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed
1.6field-weighted citation impact, top 14% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 29 citations in OpenAlex.
- Promising Targets and Drugs for Improving Head and Neck Cancer Response to Radiotherapy.Current pharmaceutical design · 2026Review
- Article
- Underlying effect of SMAD4 gene polymorphism on risk prediction of papillary thyroid carcinoma in Chinese population.Heliyon · 2024Article
- Dysregulation of exosomal miRNAs and their related genes in head and neck cancer patients.Future oncology (London, England) · 2024Article
- Tumor-related IGF2BP1-derived molecular subtypes to predict prognosis and immune microenvironment in head and neck squamous cell carcinoma.Frontiers in immunology · 2024Article
- TGF-β signaling in health and disease.Cell · 2023Review
- SMAD Proteins in TGF-β Signalling Pathway in Cancer: Regulatory Mechanisms and Clinical Applications.Diagnostics (Basel, Switzerland) · 2023Review
- DNA Damage Response Mechanisms in Head and Neck Cancer: Significant Implications for Therapy and Survival.International journal of molecular sciences · 2023Review
- Attenuation of Tumor Burden in Response to Rucaparib in Lung Adenocarcinoma: The Contribution of Oxidative Stress, Apoptosis, and DNA Damage.International journal of molecular sciences · 2023Article
- Epidermal growth factor receptor signaling in precancerous keratinocytes promotes neighboring head and neck cancer squamous cell carcinoma cancer stem cell-like properties and phosphoinositide 3-kinase inhibitor insensitivity.Molecular carcinogenesis · 2022Article
- HPV-mediated regulation of SMAD4 modulates the DNA damage response in head and neck cancer.Journal of experimental & clinical cancer research : CR · 2022Article
- Why responses to immune checkpoint inhibitors are heterogeneous in head and neck cancers: Contributions from tumor-intrinsic and host-intrinsic factors.Frontiers in oncology · 2022Review
- Effectiveness of PARP inhibition in enhancing the radiosensitivity of 3D spheroids of head and neck squamous cell carcinoma.Frontiers in oncology · 2022Article
- Targeting DNA damage response as a potential therapeutic strategy for head and neck squamous cell carcinoma.Frontiers in oncology · 2022Review
- Research on Anal Squamous Cell Carcinoma: Systemic Therapy Strategies for Anal Cancer.Cancers · 2021Review
- PARP1 Upregulation in Recurrent Oral Cancer and Treatment Resistance.Frontiers in cell and developmental biology · 2021Article
- Recent advancements in PARP inhibitors-based targeted cancer therapy.Precision clinical medicine · 2020Review
- Combining PARP and DNA-PK Inhibitors With Irradiation Inhibits HPV-Negative Head and Neck Cancer Squamous Carcinoma Growth.Frontiers in genetics · 2020Article
- Radiotherapy and the cellular DNA damage response: current and future perspectives on head and neck cancer treatment.Cancer drug resistance (Alhambra, Calif.) · 2020Review
- DNA damage response and potential biomarkers of radiosensitivity in head and neck cancers: clinical implications.Romanian journal of morphology and embryology = Revue roumaine de morphologie et embryologieReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 3 institutions in 2 countries.
Ariel L Hernandez *Department of Pathology, School of Medicine, University of Colorado, Anschutz Medical Campus, Aurora, Colorado.ORCID 0000-0002-3656-185X
Christian D Young *Department of Pathology, School of Medicine, University of Colorado, Anschutz Medical Campus, Aurora, Colorado.
Li BianDepartment of Pathology, School of Medicine, University of Colorado, Anschutz Medical Campus, Aurora, Colorado.ORCID 0000-0001-9916-3720
Kelsey WeigelDepartment of Pathology, School of Medicine, University of Colorado, Anschutz Medical Campus, Aurora, Colorado.
Kyle NolanDepartment of Pathology, School of Medicine, University of Colorado, Anschutz Medical Campus, Aurora, Colorado.
Barbara FrederickDepartment of Radiation Oncology, University of Colorado, Anschutz Medical Campus, Aurora, Colorado.
Gangwen HanDepartment of Pathology, School of Medicine, University of Colorado, Anschutz Medical Campus, Aurora, Colorado.
Guanting HeDepartment of Pathology, School of Medicine, University of Colorado, Anschutz Medical Campus, Aurora, Colorado.
G Devon TrahanDepartment of Pediatrics, Section of Hematology, Oncology, and Bone Marrow Transplant, University of Colorado, Anschutz Medical Campus, Aurora, Colorado.
Michael C RudolphDepartment of Medicine, Division of Endocrinology, Metabolism, and Diabetes, University of Colorado, Anschutz Medical Campus, Aurora, Colorado.
Kenneth L JonesDepartment of Pediatrics, Section of Hematology, Oncology, and Bone Marrow Transplant, University of Colorado, Anschutz Medical Campus, Aurora, Colorado.
Ayman J OweidaDepartment of Nuclear Medicine and Radiobiology, Université de Sherbrooke, Sherbrooke, Quebec, Canada.
Sana D KaramDepartment of Radiation Oncology, University of Colorado, Anschutz Medical Campus, Aurora, Colorado.
David RabenDepartment of Radiation Oncology, University of Colorado, Anschutz Medical Campus, Aurora, Colorado.
Xiao-Jing WangDepartment of Pathology, School of Medicine, University of Colorado, Anschutz Medical Campus, Aurora, Colorado. xj.wang@cuanschutz.edu.ORCID 0000-0001-8695-7361
University of Colorado Anschutz Medical Campus · USUniversité de Sherbrooke · CAVA Eastern Colorado Health Care System · US
Funding
University of Colorado Cancer Center Support Grant - Lung Cancer Patient-Derived Xenografts with Autologous Human Immune SystemsP30CA046934 · NCI · UNIVERSITY OF COLORADO DENVER · PI James V Degregori · 1988 to 2026
$117.0MTargeting PD-L1 interactome signaling to enhance immunotherapy efficacy in head and neck squamous cell cancerR01CA149456 · NCI · UNIVERSITY OF COLORADO DENVER · PI Antonio Jimeno · 2010 to 2026
$5.6MTraining in Translational Research of Lung, Head and Neck CancerT32CA174648 · NCI · UNIVERSITY OF COLORADO DENVER · PI KARAM, SANA D · 2013 to 2022
$4.2MRole of TGFbeta signaling in HNSCC progressionR01DE015953 · NIDCR · UNIVERSITY OF COLORADO DENVER · PI WANG, XIAO-JING · 2004 to 2014
$3.6MIdentifying oral cancer stem cell properties affected by the microenvironmentR01DE024371 · NIDCR · UNIVERSITY OF COLORADO DENVER · PI JIMENO, ANTONIO, WANG, XIAO-JING · 2014 to 2017
$2.1MPodoplanin-positive carcinoma-associated fibroblasts drive progression and metastatic potential of head and neck squamous cell carcinomaF32DE027285 · NIDCR · UNIVERSITY OF COLORADO DENVER · PI WEIGEL, KELSEY J · 2017 to 2017
$37kMechanisms of Breaking Indolence in Squamous Cell CarcinomaI01BX003232 · VA · VA NORTHERN CALIFORNIA HEALTH CARE SYS · PI WANG, XIAO-JING · 2017 to 2025
–BLRD VA I01 BX003232NCI NIH HHS P30 CA046934NCI NIH HHS R01 CA149456NCI NIH HHS T32 CA174648NIDCR NIH HHS F32 DE027285NIDCR NIH HHS R01 DE015953NIDCR NIH HHS R01 DE024371
Abstract
purposeEXPERIMENTAL
designWe analyzed HNSCC The Cancer Genome Atlas data for
results
conclusions
Indexed as
Disease Models, AnimalAnimalsAntineoplastic Combined Chemotherapy ProtocolsApoptosisCell ProliferationCetuximabFemaleHead and Neck NeoplasmsHumansMiceMice, NudePhthalazinesPiperazinesPoly(ADP-ribose) Polymerase InhibitorsPrognosisSmad4 ProteinCetuximabolaparibPhthalazinesPiperazinesPoly(ADP-ribose) Polymerase InhibitorsSmad4 ProteinSMAD4 protein, human
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.